Cereno Scientific is preparing to submit an application to start Phase II study

Report this content

Cereno Scientific is preparing to within shortly submit a clinical trial application regarding the company’s Phase II study with its drug candidate CS1. This means that the application will be submitted earlier than in the third quarter of 2019, which was previously communicated. The company’s intention is to initiate the study during the first half of 2020, provided the approval of the relevant authorities and the ethics committee and that sufficient study material has been produced.

“Cereno Scientific, together with its partner Galenica and the CRO company OCT Group has been working hard on this application for the last few months and we are happy to submit it earlier than planned. We look forward to continuing with the next study for our drug candidate CS1, which has shown positive results in previous preclinical and clinical studies,” says Cereno Scientific’s CEO Sten R. Sörensen.

The Phase II study will be conducted at approximately 30 clinics in Russia and Bulgaria in collaboration with the Russian CRO company OCT Group and will be performed on patients undergoing orthopedic surgery. Cereno Scientific’s drug candidate CS1 has the potential to redefine the thrombosis prevention field by enhancing the body’s own clot-busting system instead of inhibiting the blood’s coagulation ability. The risk of blood clots increases during surgery and the aim of the study is to show the effect of the drug candidate CS1, as a prevention of thrombosis.

For further information, please contact:
Sten R. Sörensen – CEO
Tel: +46 733 74 03 74
E-mail: sten.sorensen@cerenoscientific.com

About Cereno Scientific AB
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.


Documents & Links